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dtted gene transfer with the LASN vector. After 2 y of polyethylene glycol-ADA treatment and before gene therapy, she cwtinued to experience recurrent infecths, was 8nergic and lymphopenic, and was deficient in isohemagglutiains. After seven infusions totali-7 x 10" T cells, she has demonstrpted a substantial iaaerse in the namber d chdating T cells (5711pL pregene therapy wmu a mean of 19951pL with gene therapy infusions every 6-8 wk) and the ADA activity in her peripheral blood T cells has i n c r d ~10-fold. The increPse in T-cell numbers and ADA activity lus been associated with the develop ment of positive delayed-type hypersensitivity skin tests, a siga5cant increme in the level of isokm&nias, the rqpwth of toasils, and a decread npmber of i n f a iksms. This improvement has persisted dllring suspensioa of treatment for more than 6 mo. A s e c d patient treated since F e r n 1991 has shown simihr improvement in immune status. Both jmtients have tolerated the treatments without complication and are able to participate h function, may offer the only effective treatment for some eases. In practice, the challenges of this approgch have proven tcr be f -, but fmally early plognss in clinical application is being made.
l l y i P s c b o o l d d 8 c t i v i t i e d I ' h e s e~d e m -

T h e d e v c l o p m e n t o f g a r t~f i J r s n y~d i s e o s e f i r s t requires the identification and cloning dtht gene responsible
for that condition. Of the primary immunodeficiency diseases ncognized by the World Health organbation (2), the genes for only four have so far been cloned (ADA deficiency, purine nucleoside phosphorylase deficiency, chronic granulomatous disease, and leukocyte adhesion defect). Once the gene has been * .
isolated, its function must be understood before work can begin on developing a method to deliver that gene to the proper cells. This gene delivery may have to be at a specific time during cellular development, and the gene may need to be expressed in a specific geographic location within the cell. It may be necessary to provide for tightly regulated expression of the gene depending on the cell's position in the cell cycle or to respond to critical intmcellular messenger molecules. It might be neoessary to w ardinaXe the timing and level of expression of the inserted gene with that of other genes within the cell. In addition, it may be neces~ary to achieve very bigb efficiency gene transfer lest the residual defective "noncorrectedw cells -ensure that somatic cells alone will be sene modifisd. s% BLAESE possible to apply systemically (e.g. electroporation). Ex vivo treatment also potentially allows various selection procedures for g e n e m d e d cells to be used (e.g. G418 selection for NeoR gene function). Finally, ex vivo treatment can provide some opporhmity for safety testing of the genemodiki cells Wore their reimplantation into the patient.
Clonhg of the involved gene is just one step in developing gene therapy for a specific disease. The function of that gene and its product must be thoroughly understood before a rational plan can be devised for genetic correction. Some genes may encode for developmentally critical factors that must be active during embryonic/fetal growth for the proper cells to differentiate. In that case, it just may not be possible to fbnctionally correct the disease in postnatal life because potentially responsive precursor cells or diffmntiative signals from other cells in the environment are no longer available. Other genes could encode for products that are under very close physiologic regulation (e.g. insulin), and those regulatory components might have to be replaced in conjunction with the defective gene. The best initial candidates for gene therapy would be diseases involving a relatively simple "housekeepingw gene that does not require close regulation and whose function is not absolutely critical to the differentiation and development of the affected cell lineage.
For a corrective gene to be inserted into the lymphohematopoietic stem cell, a process that will give highly efficient stable integration of the inserted gene must be a major feature of the transfer system. Otherwise, as the stem cell proliferates and differentiates, the inserted gene could be progressively diluted out and eventually lost from, or unevenly distributed in, the mature erythroid, myeloid, and lymphoid lineages. Gene insertion into a terminally differentiated, nonproliferative tissue such as skeletal muscle or liver might not need integration as a feature of the gene transfer system. Because the immune system so extensively involves cells that proliferate actively during differentiation and also as a consequence of later activation, an integrated gene is probably essential for this population and techniques to provide this feature are the focus of most studies.
I
The Moloney murine leukemia-based retroviral vectors have I distinct advantages for gene therapy of proliferating tissues like the lymphoid system (,4). Most importantly, these vectors integrate into the chromosomes of the w e t cell and thereafter become a stable part of the inheritance of that cell, being passed along to all cell progeny during normal cell division. In addition, retroviral vector systems can be highly efficient for gene transfer, exceeding 90% in some cell types in vitro. Potential disadvantages of retroviral vectors indude the fact that they randomly integrate into the host cell genome, which could have several unfavorable consequences. Random integration implies that each individual transduced cell could behave differently from another cell with a different vector integration site. The local environment of the chromosome where integration occurs ( tage will probably require preparative cytoreduction to allow sufficient engraftment of the genetically corrected cells to achieve full reconstitution. The need for cytoreduction will increase the morbiditv and mortalitv of the ~rocedure as it does with conventional bile marrow &splant&on. However, gene therapy with autologous cells will still have the advantage of a very low risk of graft-versus-host disease. Stem cell gene modification has been under intensive investigation in many laboratories. Initial interest centered on the hemoglobinopathies as candidate diseases for gene therapy, with globin gene transfer with retroviral vectors the primary goal (1). In murine systems, several genes have been successfully transferred to the hemopoietic stem cells, resulting in long-term expression in animals that have undergone transplantation.
Unfortunately, attempts to duplicate these results in larger animals were unsuccessu (8). The S A X retroviral vector was found to readily introduce a corrective ADA gene into cultured human ADA-T cells in vitro. However, when the same vector was used to treat freshly collected bone marrow from rhesus or cynomologus monkeys that had been lethally irradiated before remnstitution by transplantation with the "genatreated" autologous marrow, different results were obtained. Some recipients did produce human ADA in their circulating PBMC, but the level of gene expression was low and disappeared within a few weeks to months (9). Although these studies were disappointing in that stable, long-term gene expression was not achieved, they did demomtmte that retroviral vectors could transfer genes into primate cells and that some gene expression could be detected in peripheral cells after bone marrow treatment. In addition, the gene transfer procedure appeared to be safe in that no complications related to the use of genemodified cells were observed. Among the factors that contribute to the hilure of these experiments, one is the fact that totipotent stem cells are usually in a nonproliferative (Go) state, whereas the retroviral gene transfer system used is only effective in introducing genes into proliferating cells. Thus, genes were probably introduced into a more mature proliferating progenitor population that gave transient expression of the gene before the cells reached senescence, only to be replaced by more primitive cells that had not been in cycle earlier and thus had not acquired the gene. Two strategies have been followed in an attempt to improve these results: I) the & of growth h r s to induce the totipotent stem cells to proliferate, and 2) procedures to enrich the stem cells in the population exposed to the retroviral vector. In addition, we began a series of studies exploring the use of alternative cellular vehicles for gene therapy, specifically T lymphocytes, These studies in rodents and =o&ys did demonstrate that mature peripheral T cells could be successllly modified by retroviral-mediated gene transfer and that the genemodified cells penisted for prolonged periods and continued to express the introduced genes when reinfusad into the donor animals.
ADA DEFICIENCY
ADA deficiencv is inherited as an autosomal recessive disorder.
TRANSPUNTATION FOR IMMUNODEFICIENCY
At the molecular-and genetic level, ADA deficiency is the most extensively studied of all the congenital immunodeficiency disBecause bone marrow can be treated easily ex vivo, diseases eases because it was the first of the immunodeficiency diseases that can be treated by allogeneic bone marrow transplantation in which the molecular defect was identified (10) and the first in have become the leading candidates for the initial attempts at which the gene was cloned (1 1-13 ). This deep understanding of tions and failure to thrive appeared to be significantly reduced after institution of enzyme replacement. This clinical improvement was seen even in some patients who failed to demonstrate objective measures of reconstituted specific immune functions, such as antigen-induced T-cell proliferation or the development of positive skin tests. Finally, cultured T cells were being used successfully in the treatment of cancer, so this new approach to cellular therapy had some clinical precedent.
T-LYMPHOCYTE GENE THERAPY FOR ADA DELlCIENCY
Our preclinical experiments in mice and monkeys demonstrated prolonged survival of genetically altered T cells with continued expression of the inserted genes in vivo (23, 24) . Primary T-cell cultures were established from five ADA-SCID patients, and a portion of each culture was genetically corrected after retroviral-mediated transduction with the LASN vector. (Table 1 ). These observations suggested that production of ADA in an intracellular location provides a survival advantage to the cells even though the cells were not being challenged with exogenous dAdo in this culture situation.
Ferrari et al. (26) took these observations one step further by transferring ADA-SCID T cells from a child receiving PEG-ADA into immunodeficient BNX mice with and without transduction with a human ADA gene vector. Even though these animals are ADA normal and thus do not have elevated tissue or body fluid levels of &do, only the BNX mice that received ADA genecorrected cells showed evidence of survival of the patient's T cells. These studies also showed that the surviving human T cells were capable of mediating some T-cell effector functions in vivo. Taken together, these findings suggest that the insertion of a normal ADA gene into the T cell, providing for constitutive intracellular ADA vroduction. eives a survival and functional advantage to those 'cells beyo*dwthat which can be obtained by surrounding the cells with ADA enzyme in the extracellular medium orbody fluids.
The Recombinant DNA Advisory Committee of the National Institutes of Health approved a trial of T-cell gene therapy for the treatment of ADA-SCID with LASN-transduced T cells in July 1990. After Food and Drug Administration approval, the first patient was treated on September 14, 1990, and a second child started treatment in January 199 1. Each patient had been treated with regular injections of PEG-ADA for at least 2 y, and both, despite significant clinical improvement, had documented persisting immunodeficiency before beginning gene therapy. The original child had significant T lymphopenia, skin test anergy, absent cytolytic T-cell activity for influenza or allogeneic target cells, depressed IL-2 production, and deficient isohemagglutinins and antibody responses. The second patient had presented at an older age and had less severe disease. However, this patient was also deficient in isohemagglutinins and antibodies to recent environmental exposures and had depressed cellular immune responses.
To obtain a broad sample of the immune T-cell repertoire of the patients for genetic correction, it was decided to collect peripheral blood T cells on each periodically over approximately 1 y, genetically correct those T cells in culture, and then reinfuse the "curedn T cells. Accordingly, every 4-12 wk, the children undergo apheresis to obtain PBMC. The PBMC are placed in culture with OKT-3 (Ortho Pharmaceutical Corp., Raritan, NJ) and recombinant IL-2, which stimulate vigorous T-cell proliferation. Twenty-four h after initiation of culture, the proliferating cells are exposed to the LASN retroviral vector. Using this supernate transduction procedure, 1-10% of the cultured ADA-T cells acquire and express the ADA gene. After 9 to 12 d in culture, the T cells, which have expanded by 50-to 100-fold in number, are reinfused i.v. This short-term culture process is used to minimize any tendency of the cultured T cells to develop the oligoclonality known to occur with long-term in vitro culture. Using MAb analysis of TCR-fl V region gene use, we have detected no evidence that oligoclonality has developed in the cell populations infused. No in vitro G4 18 or 2'-dAdo selection for gene-expressing cells has been used because there is a natural selection process in vitro and presumably in vivo for ADA+ cells.
After seven infusions totaling 7 x 10" T cells, the first patient has demonstrated a substantial increase in the number of circulating T cells and the ADA activity in her peripheral blood T cells has increased > 10-fold. The increase in T-cell numbers and ADA activity has been associated with the development of positive delayed-type hypersensitivity skin tests, isohemagglutinins, cytolytic T cells, and IG2 production, the regrowth of tonsils, and a decreased number of infectious illnesses (Table 2) . Several critical observations have been made to date during this ongoing study (27) . The ADA gene-corrected cells have continued to be detectable in the blood of both children since the first treatment, and these cells have persisted in the blood despite the discontinuation of T-cell infusions for more than 6 mo in the first patient. This demonstrates that the infused ADA gene-corrected T cells may survive for many months and that the survival advantage seen in vitro and with bone marrow transplantation is also true for these gene-corrected T cells when they are returned to the patients. Importantly, the ADA level in the circulating T cells of patient 1 has also remained elevated, indicating that expression of the introduced gene is also persisting. Both patients have tolerated the treatments without compli- The first child that we tnatea had a use of monodona1 antibody aiBGty sebSm to mrich for CaZ ells speci6caUy, in an attempt to achieve a better balance of gene correction than we have seen to date. As for proliferative respnses, those have increased. Cytokine production and L 2 production to a number of the ditkmt antigens have inneased very substantially when compared with pmreatment levels. The T cells from our first patient now pml8erate quite well to most antigens, although not to all of them. For example, she has a positive skin test, but she does not proliferate to tetanus toxoid in vitro.
Dr experiment in an Italian patient: he took the ADAdeficient T cells, gave them to immunodeficient mice, and then showed that these ADA-deficient cells disappear within a few days. If you genecorm3 those cells and put them into the immunodeficient mouse, they are able to hnction quite well for a number of months. Obviously those mice do not have a problem with ADA; they have low dAdo levels. This also suggests that there is an advantage to having the gene product (ADA) produced intracellularly.
Dr. Ochs: That is the crux of the matter. Do you think you are doing more than just a very nicely targetd ADA-replacement therapy? Are you really doing gene therapy?
Dr. Blaese: We are using genes to target the production of ADA to the T cells.
Dr. Ochs: So are you just a notch higher in sending the ADA to the place where it is needed? Dr. Blaese: How is that different from gene therapy? It is a semantic argument. I think that the treatment seems to be beneficial to the children, and I think the ADA is coming from the gene we are putting in.
Dr. Ochs: One way to solve that, at least on a practical level for those of us who take care of these patients, is to select a patient who does not respond to PEG-ADA. We have seen a patient from Steve Douglas who would be an ideal case, and I have talked to you about this before. This is the kind of patient I think we really need to push to gene therapy, because we should not forget that all these patients Dr. Hershfield is treating are on PEG-ADA, and I hear different interpretations. I hear that they do very well on PEG-ADA, or they did relatively well before gene transfer therapy. I would strongly recommend that those of you who are on the trigger with these patients select at least one patient who does not respond to PEG-ADA.
Dr. Blaese: We studied Steve Douglas' patient extensively in vitro. That child's T cells do grow polyclonally in our system, and it is very easy to get the gene in and get it expressed in high levels. Steve has been reluctant to enter this patient in the protocol, and so we have not been able to do gene transfer therapy. There are other patients that we have evaluated. One was the second patient in Dr. Hershfield's series. Unfortunately, that child now has an abeolute lymphocyte count of only 75, and it is very hard for us to get enough T cells from that patient to do the gene therapy by our current technique. We certainly want to do it. But that is another problem: ifa patient is severely deficient, we are not going to get enough peripheral T cells to be able to genecorrect. I am somewhat concerned that if we take apheresed lymphocytes from a child who has a very restricted circulating T-cell repertoire, out in the periphery, we may end up with oligoclonal T-cell expansion. This, in turn, could cause autoimmunity such as hemolytic anemia as a result of imbalance in the immunomgdatory T cells.
Dr. Gelfand: And that is not withstanding the fact that you are also counting on the patient's cells to respond to OKT-3 plus I L 2 to increase the efficiency of gene transfer. You have many obstacles to overcome. Dr. GeIfand: So the argument remains that the cell that has endogenous ADA activity in it does better than the cell exposed to ADA in the plasma. And I guess that is still part of the argument.
Dr. B k Well, that is what the transfer experiments in the mouse suggest, and our cell line data also suggest that. I think the relative immune response rate that we have seen in our patients also suggests that these children are doing somewhat better than they were before. That is not to say that the PEG-ADA is not important. It is critical to our approach that they do well enough on PEG-ADA to allow us to try this approach to gene therapy.
Dr. Ballow: For those patients that have severe lymphopenia, do you anticipate a two-step approach in which you might take bone marrow first and then go to peripheral blood? Dr. Blaese: The protml that we have submitted for consideration at the March Recombinant DNA Advisory Committee meeting will look at CD34selected peripheral stem cells, and we are going to be using a retrovirus vector different from the one that we use with T cells. We will continue treatment with T cells, but well add a couple of peripheral stem cell mtments. Then later on we will be able to distinguish, by polymerase chain reaction, which of the populations is working. We do not know ifwe can get the gene into the stem cell, but Ithink it is an important experiment to do now that we are confident that this is a reasonably safe p d u r e . Dr. Strober: Have you consiinserting (along with the retrovirus vector) a gene segment that decodes the T-cell receptor for a particular antigen, and then getting expression of that Tcell receptor on the surface of the cells that are transfected with the retrovirus? Could you then bump up the number of T cells by simply immunizing the patient? Dr. Blaese: That would not work in this disease. It would be potentially very usem if you wanted to have T cells make factor W I or factor IX for hemophilia, for instance. Then you could come back and hit them with the antigen to continually reexpand the cells engineered to produce the clotting factors. However, I
am not sure that picking one or even a handful of spdicities would be particularly wise in ADAXID. We want to get polyclonal immune nconstitution in these children. It is conceivable that if you made a suppressor T cell to a particular antigenic epitope you would shut down not only that specificity but other cells with different qxxificities, and this would result in the loss of the polyclonal repertoire. 
